Back to top
Alkermes (ALKS)
(Real Time Quote from BATS)
$26.52 USD
26.52
359,173
-0.07 (-0.26%)
Updated Oct 10, 2024 12:12 PM ET
3-Hold of 5 3
A Value A Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$26.52 USD
-0.07 (-0.26%)
Updated Oct 10, 2024 12:12 PM ET
3-Hold of 5 3
A Value A Growth A Momentum A VGM
View All Zacks #1 Ranked Stocks
Zacks News
ResMed (RMD) Inks Deal to Acquire MEDIFOX DAN in Germany
by Zacks Equity Research
ResMed's (RMD) acquisition of a renowned out-of-hospital software solutions company is expected to strengthen its SaaS business.
Here's Why You Should Hold Quest Diagnostics (DGX) Stock Now
by Zacks Equity Research
Investors are optimistic about Quest Diagnostics (DGX) owing to a strong recovery in its base business and encouraging 2022 guidance.
Moderna's (MRNA) COVID-19 Vaccine Nears EUA in Pediatrics
by Zacks Equity Research
An FDA advisory committee voted in favor of the use of Moderna's (MRNA) COVID-19 vaccine in individuals aged 6 years to 17 years. A meeting to discuss the use of the vaccine in the younger population is scheduled for today.
Valneva (VALN) Down on its COVID-19 Vaccine Update in Europe
by Zacks Equity Research
Valneva (VALN) slides on a proposed remediation plan update after receiving the European Commission's notice of intent to terminate the Advance Purchase Agreement for its COVID-19 vaccine.
Endo (ENDP) Inks Deal for Osteoarthritis Knee Pain Drug
by Zacks Equity Research
Endo (ENDP) collaborates with Taiwan Liposome to commercialize TLC599, an extended and controlled release liposomal formulated dexamethasone for chronic knee osteoarthritis (OA) pain.
Charles River (CRL) to Create New Gene Therapy for Hemophilia A
by Zacks Equity Research
Charles River (CRL) will work with ASC Therapeutics to manufacture a second-generation gene therapy for hemophilia A.
Here's Why You Should Hold on to Teleflex (TFX) Stock for Now
by Zacks Equity Research
Investors are optimistic about Teleflex's (TFX) better-than-expected results and strong growth within the vascular business.
Merck (MRK) Keytruda Adjuvant Lung Cancer sBLA Accepted by FDA
by Zacks Equity Research
The FDA is expected to give its decision on Merck's (MRK) Keytruda sBLA for adjuvant stage IB-IIIA NSCLC, following complete surgical resection, on Jan 29, 2023.
Align (ALGN) Hurt by Dental Practice Closures, FX Headwind
by Zacks Equity Research
Align (ALGN) competes with products similar to Invisalign Technology, such as the products from Ormco Orthodontics, a division of Sybron Dental Specialties.
ImmunoGen (IMGN) Enters New Collaboration to Boost ADC Pipeline
by Zacks Equity Research
ImmunoGen (IMGN) inks a collaboration deal with privately-held Oxford BioTherapeutics to develop novel antibody-drug conjugates by complementing each other's proprietary technologies.
FDA Committee Endorses bluebird's (BLUE) Thalassemia Therapy
by Zacks Equity Research
An FDA advisory committee favors approval for bluebird bio's (BLUE) beti-cel to treat transfusion-dependent thalassemia. A final decision by the regulatory body is expected on Aug 19, 2022.
Here's Why Investors Should Retain Chemed (CHE) Stock Now
by Zacks Equity Research
Strong performance across Chemed's (CHE) Roto-Rooter arm and increased home-based admissions raise investors' confidence.
Here's Why Investors Should Retain SmileDirectClub (SDC) Now
by Zacks Equity Research
Investors are optimistic about SmileDirectClub's (SDC) better-than-expected revenues and new product launches.
Cogent (COGT) Surges on Robust Data from Mastocytosis Study
by Zacks Equity Research
Cogent's (COGT) bezuclastinib achieves robust effectiveness in patients with advanced systemic mastocytosis with a favorable safety and tolerability profile. Stock surges more than 58% on Jun 10.
Bristol Myers (BMY) Up 20.4% YTD: Will the Momentum Continue?
by Zacks Equity Research
Bristol Myers (BMY) has put up an impressive performance so far in 2022, and the momentum should continue.
GSK's RSV Vaccine Candidate Offers Robust Protection in Elderly
by Zacks Equity Research
GSK's RSV vaccine candidate for adults aged 60 years or above achieves statistically significant and clinically meaningful efficacy in a phase III study. Regulatory submissions are likely in the second half of 2022.
LabCorp (LH) Rides on Innovations Amid Cost Constraints
by Zacks Equity Research
LabCorp's (LH) slew of product launches and collaborations to pursue short- and long-term high-growth opportunities instill optimism.
Zacks Industry Outlook Highlights Alkermes, Geron, Immunocore and BELLUS Health
by Zacks Equity Research
Alkermes, Geron, Immunocore and BELLUS Health have been highlighted in this Industry Outlook article.
FDA Committee Recommends bluebird's (BLUE) CALD Therapy
by Zacks Equity Research
An FDA advisory committee supports approving bluebird bio's (BLUE) eli-cel for treating cerebral adrenoleukodystrophy. NASDAQ halts trading BLUE's common stock on Jun 9 and 10.
4 Biotech Stocks With Bright Prospects to Buy Amid Recovery
by Zacks Equity Research
New drug approvals and development of treatments for COVID-19 should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and pipeline progress position ALKS, GERN, IMCR and BLU well amid the volatility.
Abbott (ABT) Medical Devices Arm Gains Traction, FX Woe Stays
by Zacks Equity Research
Within Abbott's (ABT) Nutrition arm, while the pediatric nutrition business witnesses a drag, the adult nutrition business continues to perform well.
Amedisys (AMED) Contessa's New JV Broadens At-Home Care Range
by Zacks Equity Research
Amedisys' (AMED) latest initiative aims at providing patients with a high-quality continuum of care in the home.
Thermo Fisher's (TMO) Autoimmune Disease Test Gets FDA Nod
by Zacks Equity Research
Thermo Fisher's (TMO) RNA Polymerase III and EliA Rib-P blood tests are intended to diagnose systemic sclerosis and systemic lupus erythematosus.
Moderna's (MRNA) Omicron-Specific Booster Jab Meets Study Goal
by Zacks Equity Research
Moderna's (MRNA) bivalent COVID booster candidate targeting the Omicron variant achieved all pre-specified endpoints in a phase II/III study.
Rigel (RIGL) wAIHA Study Fails to Meet Goals, Stock Tanks
by Zacks Equity Research
Rigel (RIGL) phase III study evaluating fostamatinib in patients with warm autoimmune hemolytic anemia did not demonstrate statistical significance in the primary efficacy endpoint.